drugset / Trial / NCT02795143
Evaluating the Effect of Isotretinoin in Regulatory T-cell Function in Adverse Cutaneous Drug Eruptions (ACDEs): A Pilot Study
Withdrawn
Massachusetts General Hospital
RandomizedParallel-groupTriple-blindTreatment
Summary
The purpose of this study is to determine whether isotretinoin is helpful in treating patients with an adverse cutaneous drug eruption known as toxic epidermal necrolysis (TEN).
Timeline
- Start
- 2016-11
- Primary completion
- 2020-06
- Completion
- 2020-06
Outcome
Outcome not reported
Stopped (Enrollment): “PI (Responsible Party) transferred to new institution prior to enrollment and protocol was closed.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Isotretinoin | Other / unclassified | 40 mg | Oral |
| Subject | Isotretinoin | Other / unclassified | 80 mg | Oral |
| Subject | Isotretinoin | Other / unclassified | 120 mg | Oral |